Topcon Healthcare has acquired RetInSight GmbH, a privately held company based in Vienna, Austria, renowned for its innovation in retinal imaging artificial intelligenve (AI) solutions. The move advances Topcon Healthcare’s vision of Healthcare from the Eye, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs, and improve clinical outcomes.
RetInSight’s AI algorithms analyse optical coherence tomography (OCT) images captured in routine clinical care to detect and monitor major retinal diseases – geographic atrophy, neovascular age-related macular degeneration, diabetic macular oedema, and retinal vein occlusion – which are the leading causes of vision loss globally. These tools enable earlier intervention and personalised treatment planning, especially for aging populations.
This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide
“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally,” said Professor Hans Peter Schwarz, Chairman of the Board of RetInSight. “This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”
RetInSight’s platform, born from pioneering research at the Medical University of Vienna, Department of Ophthalmology and Optometry, under the direction of Professor Ursula Schmidt-Erfurth, is already commercialised throughout Europe and is vendor-inclusive supporting interoperability across multiple OCT systems.
“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” said Ali Tafreshi, Chief Executive Officer and President of Topcon Healthcare, Inc. “Integrated with our Harmony vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”
Already used in pharmaceutical trials, RetInSight’s algorithms also support AI-powered drug development and regulatory pathways, including advancing Food and Drug Administration clearances for US indications.
“Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”
